Pfizer Slashes 2020 Production Target By 50% Due To Supply Chain Challenges

Pfizer cited later-than-expected results from Pfizer's clinical trial as a reason for the smaller number of doses expected to be produced by the end of 2020

Challenges in Pfizer Inc’s supply chain for the raw materials used in its Covid-19 vaccine played a role in its decision to slash its 2020 production target, a Pfizer spokeswoman told Reuters.

Pfizer has said in recent weeks that it anticipates producing 50 million doses of its Covid-19 vaccine this year. That is down from an earlier target of 100 million doses. Pfizer’s vaccine relies on a two-dose regimen, meaning 50 million doses is enough to inoculate 25 million people.

A company spokeswoman said the “scale-up of the raw material supply chain took longer than expected.” She also cited later-than-expected results from Pfizer’s clinical trial as a reason for the smaller number of doses expected to be produced by the end of 2020.

The spokeswoman added that the modifications to Pfizer’s production lines are now complete and finished doses are being made at a rapid pace.

The Wall Street Journal was the first to report the news. It reported that an unnamed person directly involved in the development of the Pfizer vaccine said “some early batches of the raw materials failed to meet the standards,” which caused production delays.

Pfizer applied in November for emergency authorization for its Covid-19 vaccine from U.S. regulators. U.S. officials said they expect its vaccine to get regulatory clearance this month. The U.S. government expects its first allocation of the vaccine to include 6.4 million doses, with more to follow.

Regulators in the U.K. have already authorized Pfizer’s vaccine for use in that country.

What is a cold chain?

According to WHO, ‘the role of the cold chain is to maintain the potency of vaccines from the point of manufacture to the point of use.’

From reaching the factory to the syringe, making the task of securing “last mile connectivity” and ensuring that nothing goes wrong before the shot is administered is the need of the hour.

Cold storage is the next big challenge

The vaccine cold chain hurdle is just the latest disparity of the pandemic weighted against many countries. Investment in the infrastructure and cooling technology lags behind the high-speed leap that vaccine development has taken this year.

The initial vaccine candidates from Pfizer and Moderna are both mRNA vaccines and mRNA is naturally an unstable molecule that is prone to degradation when exposed to temperature fluctuations.

The Associated Press estimates vaccine storage issues could leave 3 billion people in developing countries without access to a coronavirus vaccine.

Maintaining the cold chain for coronavirus vaccines won’t be easy even in the richest of countries. Medical freezers that go down to minus 70 degrees Celsius are rare even in U.S. and European hospitals.

Facebook Comments